@article{Önal_Yılmaz_Eroğlu_Eroğlu_Koçer_2020, title={Survival analysis and factors affecting survival in patients with pancreatic cancer.}, volume={7}, url={https://medscidiscovery.com/index.php/msd/article/view/352}, DOI={10.36472/msd.v7i2.352}, abstractNote={<p><strong>Objective:</strong> The study aims to investigate the effects of clinicopathological characteristics and laboratory data at the time of diagnosis and of the administered treatments on survival in patients with pancreatic cancer.</p> <p><strong>Material and Methods:</strong> In this retrospective cohort study, we included the patients who presented to the Medical Oncology Outpatient Clinic of Isparta Süleyman Demirel University Medical Faculty Hospital and were diagnosed with pancreatic cancer between January 1, 2010 and December 31, 2017.</p> <p><strong>Results:</strong> A total of 124 patients were examined. The median survival time was 6.97 (%95 CI:4.663-9.270) months, and the 5-year survival rate was 8%. The survival time was shorter in patients diagnosed with adenocarcinoma (HR: 5.350), history of alcohol use (HR: 2.195), an Eastern Cooperative Oncology Group (ECOG) performance score of >2 (HR:2.763), Ca 19-9 value >400 (HR:1.790). Stages 2, 3 and 4 posed 2.034, 3.175 and 6.023 times higher risk of death than stage 1, respectively. Considering the adjuvant chemotherapy group as reference, risk of death was 1.250 times higher for those who received palliative chemotherapy and 2.314 times higher for those who did not receive chemotherapy.</p> <p><strong>Conclusion:</strong> In conclusion, history of alcohol use, Ca 19-9 level, ECOG performance status, disease stage, histopathological subtype of the disease, and whether the patient received chemotherapy or radiotherapy affect survival in patients with pancreatic cancer.   </p>}, number={2}, journal={Medical Science and Discovery}, author={Önal, Özgür and Yılmaz, Servet Derya and Eroğlu, Hande Nur and Eroğlu, İsmet and Koçer, Murat}, year={2020}, month={Feb.}, pages={412–418} }